Medical Marijuana, Inc. Portfolio Company Kannalife Sciences Finalizes Share Exchange Agreement with TYG Solutions

SAN DIEGO, Aug. 1, 2018

"We are thrilled to announce the completion of this share exchange agreement," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "Our company was an early investor in Kannalife, which has developed and patented specific cannabinoid-like molecules to create a targeted approach to treat medical conditions. We believe that Kannalife's powerful portfolio of IP sets the company apart in an increasingly competitive cannabinoid pharmaceutical market arena."

Kannalife Sciences currently holds two licenses with NIH. The first, an exclusive license for the commercialization of U.S. Patent #6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent"), to research and develop novel cannabinoid-based therapeutics to treat hepatic encephalopathy (HE); and the second, a non-exclusive license under the same '507 Patent to treat chronic traumatic encephalopathy (CTE).

"The completion of our share exchange transaction with TYYG has brought us to another starting point in the company's history – now as a publicly traded company. We now find ourselves in the middle of a very exciting, resurgent and hot biotechnology space, coupled with burgeoning investor interest in 'anything cannabis,'" Kannalife Sciences CEO Dean Petkanas said. "The transaction with TYYG allows us to look toward the future as a publicly traded company and continue our research into developing disruptive cannabinoid-based therapeutics for neurodegenerative and oxidative stress-related diseases."

Further, Kannalife has developed its own patented molecules led by KLS-13019 and was recently awarded U.S. Patent #9,611,213, "Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy." These cannabidiol-derived new chemical entities (NCEs) are intended to advance some of the clinical benefits of CBD while improving upon some of the pharmacokinetic limitations of CBD. According to a February 10, 2016 publication in the American Chemical Society KLS-13019 was found to be 50-fold more potent as a neuroprotectant and >400-fold safer than cannabidiol (CBD).

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.